RAPT Therapeutics(US:RAPT) Globenewswireยท2025-05-08 12:00Core Viewpoint - RAPT Therapeutics reported a significant reduction in net loss for Q1 2025 compared to Q1 2024, alongside a focus on advancing its lead candidate RPT904 for food allergies and chronic spontaneous urticaria [3][4][5]. Financial Performance - The net loss for Q1 2025 was $17.2 million, a decrease from $30.5 million in Q1 2024 [3]. - Research and development expenses were $12.0 million in Q1 2025, down from $24.8 million in the same period of 2024, primarily due to reduced costs associated with other drug developments [4]. - General and administrative expenses decreased to $7.2 million in Q1 2025 from $7.7 million in Q1 2024, attributed to lower personnel and professional service costs [5]. - As of March 31, 2025, the company had cash and cash equivalents and marketable securities totaling $179.3 million [5]. Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases, leveraging proprietary expertise in immunology [6].